Oxaliplatin
Ingredients
Oxaliplatin
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| OxaliplatinIngredients |
|
61825-94-3 | 56 |
Indication
It can be used alone or in combination with fluorouracil for patients with colorectal cancer metastasis who have failed treatment with fluorouracil.
Usage and Dosage
For adult use only. For adjuvant therapy, the recommended dose of oxaliplatin is 85 mg/m by intravenous drip, repeated once every 2 weeks. A total of 12 cycles (6 months). For the treatment of metastatic colorectal cancer, the recommended dose of oxaliplatin is 85 mg/m by intravenous drip, repeated once every 2 weeks. The dose should be adjusted according to the patient's tolerance (see "Special Warnings and Special Precautions for Use" in [Precautions]). Oxaliplatin should be administered before infusion of fluorouracil. Dissolve oxaliplatin in 250-500 mL of 5% glucose solution (to achieve a concentration of more than 0.2 mg/mL) and infuse continuously for 2-6 hours. Oxaliplatin is mainly used in combination regimens based on continuous infusion of 5-fluorouracil. In the biweekly regimen, 5-fluorouracil is administered by a combination of push injection and continuous infusion.
Adverse Reactions
The most common adverse reactions observed during the combined use of oxaliplatin and 5-fluorouracil/leucovorin were gastrointestinal (diarrhea, nausea, vomiting, and mucositis), hematological (neutropenia, thrombocytopenia), and neurological reactions (acute, dose-accumulative, peripheral sensory neuropathy). Overall, these adverse reactions were more common and more severe when oxaliplatin was used in combination with 5-fluorouracil/leucovorin than when 5-fluorouracil/leucovorin was used alone.
Precautions
1. It is contraindicated for those who are allergic to platinum derivatives; 2. It is contraindicated during pregnancy and lactation.
Special Population Medication
Precautions during pregnancy and lactation: Contraindicated for use by pregnant and lactating women.
Storage
Keep away from light and store in sealed container.
Packaging Specification
API
Manufacturer
Wuxi Taxus Pharmaceutical Co., Ltd.
-
Founded in:
2004-05-31 -
Address:
No. 111, Qinxin Road, Donggang Town, Xishan District, Wuxi City -
Tax NO.:
9132020576243151XT -
Registered Funds:
190.31 million yuan -
Website:
-
Email: